12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

BTG, Wellstat Therapeutics sales and marketing update

Wellstat granted BTG exclusive rights to distribute uridine triacetate in the EU on a named-patient basis to treat an overdose of the chemotherapy 5-fluorouracil (5-FU). BTG also received an option to license...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >